MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer

Small-Molecule–Mediated Stabilization of PP2A Modulates the Homologous Recombination Pathway and Potentiates DNA Damage-Induced Cell Death

(2023) Rita A. Avelar et al.   MOLECULAR CANCER THERAPEUTICS

Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors

(2022) Lola Paulet et al.   EUROPEAN JOURNAL OF CANCER

PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers

(2022) Linjie Luo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

UBQLN4 promotes STING proteasomal degradation during cisplatin‐induced DNA damage in triple‐negative breast cancer

(2022) Yoshiaki Shoji et al.   Clinical and Translational Medicine

Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?

(2022) L. Musacchio et al.   ESMO Open

Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinoma

(2021) Tomohiro Murakami et al.   Molecular Oncology

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

(2021) Elizabeth M. Swisher et al.   Nature Communications

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

(2021) Lajos Pusztai et al.   CANCER CELL

Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance

(2021) Christina Andronikou et al.   TRENDS IN MOLECULAR MEDICINE

Interleukin enhancer‐binding factor 2 promotes cell proliferation and DNA damage response in metastatic melanoma

(2021) Xiaoqing Zhang et al.   Clinical and Translational Medicine

MicroRNA134 of Ventral Hippocampus Is Involved in Cocaine Extinction-Induced Anxiety-like and Depression-like Behaviors in Mice

(2020) Yuehan Li et al.   Molecular Therapy-Nucleic Acids

The Pervasive Role of the miR-181 Family in Development, Neurodegeneration, and Cancer

(2020) Alessia Indrieri et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Visualizing and interpreting cancer genomics data via the Xena platform

(2020) Mary J. Goldman et al.   NATURE BIOTECHNOLOGY

Cancer exosome-derived miR-9 and miR-181a promote the development of early-stage MDSCs via interfering with SOCS3 and PIAS3 respectively in breast cancer

(2020) Mengmeng Jiang et al.   ONCOGENE

miR-181a initiates and perpetuates oncogenic transformation through the regulation of innate immune signaling

(2020) Matthew Knarr et al.   Nature Communications

Integrated Assessment of Circulating Cell-Free MicroRNA Signatures in Plasma of Patients with Melanoma Brain Metastasis

(2020) Matias A. Bustos et al.   Cancers

Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors

(2020) Florent Peyraud et al.   Cancers

CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics

(2020) Augustin Luna et al.   NUCLEIC ACIDS RESEARCH

A miRNA-Mediated Approach to Dissect the Complexity of Tumor-Initiating Cell Function and Identify miRNA-Targeting Drugs

(2019) Anil Belur Nagaraj et al.   Stem Cell Reports

Exosome-Mediated Metastasis: Communication from a Distance

(2019) Inbal Wortzel et al.   DEVELOPMENTAL CELL

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial

(2019) Josep M. del Campo et al.   JOURNAL OF CLINICAL ONCOLOGY

DNA sensing by the cGAS–STING pathway in health and disease

(2019) Mona Motwani et al.   NATURE REVIEWS GENETICS

STING: a master regulator in the cancer-immunity cycle

(2019) Yuanyuan Zhu et al.   Molecular Cancer

PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells

(2019) Sylvie M. Noordermeer et al.   TRENDS IN CELL BIOLOGY

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

(2018) Jennifer K. Litton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Natural Killer-derived exosomal miR-186 inhibits neuroblastoma growth and immune escape mechanisms.

(2018) Paolo Neviani et al.   CANCER RESEARCH

PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness

(2018) Jianfeng Shen et al.   CANCER RESEARCH

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2

(2017) Amit M. Oza et al.   GYNECOLOGIC ONCOLOGY

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Robert L Coleman et al.   LANCET

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

(2017) Mark Robson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

(2017) Olga Kondrashova et al.   Cancer Discovery

Frequency of germline PALB2 mutations among women with epithelial ovarian cancer

(2016) Joanne Kotsopoulos et al.   Familial Cancer

Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

(2016) Susan M. Domchek et al.   GYNECOLOGIC ONCOLOGY

A Novel Approach to High-Quality Postmortem Tissue Procurement: The GTEx Project

(2015) Latarsha J. Carithers et al.   BIOPRESERVATION AND BIOBANKING

Exosome-Mediated Transfer of microRNAs Within the Tumor Microenvironment and Neuroblastoma Resistance to Chemotherapy

(2015) Kishore B. Challagundla et al.   JNCI-Journal of the National Cancer Institute

The European Genome-phenome Archive of human data consented for biomedical research

(2015) Ilkka Lappalainen et al.   NATURE GENETICS

A Novel Approach to High-Quality Postmortem Tissue Procurement: The GTEx Project

(2015) Latarsha J. Carithers et al.   Biopreservation and Biobanking

Exosome-Mediated Transfer of microRNAs Within the Tumor Microenvironment and Neuroblastoma Resistance to Chemotherapy

(2015) Kishore B. Challagundla et al.   JNCI-Journal of the National Cancer Institute

microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial–mesenchymal transition

(2014) Aditya Parikh et al.   Nature Communications

Heterozygous mutations in PALB2 cause DNA replication and damage response defects

(2013) Jenni Nikkilä et al.   Nature Communications

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells

(2012) Wanjuan Yang et al.   NUCLEIC ACIDS RESEARCH

Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA

(2012) J. Wu et al.   SCIENCE

Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway

(2012) L. Sun et al.   SCIENCE